Phase 2 Study: Efficacy and Safety of PP405 for Hair Loss

Pelage Pharmaceuticals has announced the first patients dosed in its Phase 2a clinical trial evaluating PP405 for androgenetic alopecia. The study enrolls 60 participants of all skin types and hair textures, addressing gaps in hair loss research diversity. PP405 works by reactivating dormant hair follicle stem cells through a molecular switch that targets metabolic processes regulating hair growth cycles. Phase 1 data showed proof of mechanism and strong safety profiles. The trial (NCT06393452) is randomized and placebo-controlled, with participants receiving daily topical applications. This represents a significant advancement in hair restoration, offering a non-invasive alternative to existing treatments that merely slow hair loss.